



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1646

Examiner: C. Kaufman

MAR 3 | 2003 TECH CENTER 1600/2900

In re Application of

Avi J. Ashkenazi et al.

Serial No.: 09/896,096

Filed: June 28, 2001

For:

DCR3 POLYPEPTIDE, A TNFR

HOMOLOG

CERTIFICATE OF EXPRESS MAILING

Express Mail Number: EL 809449990 US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents,

Washington, D.C. 20231.

March 21, 2003

Diane L. Marschang

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(c)

> by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

Serial No.: 09/896,096 Filed: June 28, 2001

Page 2

A copy of the items on PTO-1449 is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: March $\frac{2}{2}$, 2003

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

Mane KIllaiseha

09157

PATENT TRADEMARK OFFICE

FORM PTO-1449 MAR 2 1 2023 C

(Use several sheets if necessary)

LIST OF DISCLOSURES CITED BY APPLICANT

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. Serial No. P1134R2C2 09/896,096

Applicant

Ashkenazi et al.

Filing Date
28 Jun 2001

Group
To Be Assigned

caminer		_				
itials			Name	Class	Subclass	Filing Date
itials 1	Document Number 2002/0150583	Date 17.10.02	Mame Gentz et al	Class	REC MAR TECH CE	Filing Date EIVED 3 1 2003 NTER 1600/25

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.